Patient-Assistance Programs: Assessment of and Use by Safety-Net Clinics Kathryn Saenz Duke; Kristiana Raube; Helene Levens Lipton Disclosures Am J Health Syst Pharm. 2005;62 (7):726-731.

Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...

The same year, Novartis acquired the North American over-the-counter brand portfolio of Bristol-Myers Squibb. In 2006, Novartis announced the creation of a biomedical R&D centre in Shangai, China.

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

For the current quarter, Bristol Myers is expected to post earnings of $1.67 per share, indicating a change of -19.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +0% over ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry ...

Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum By Angus Liu Jun 12, 2025 12:43pm Bristol Myers Squibb Cobenfy Chris Boerner drug launch ...

# Bristol-Myers Squibb to acquire rights to prostate cancer drug for $350m Company News Published 06/10/2025, 06:01 PM 0 ...

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 Jun. 12, 2025 6:45 AM ET Bristol-Myers Squibb Company (BMY) ...

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.